Researchers from Suven Life Sciences Ltd. presented the discovery and preclinical characterization of a novel muscarinic acetylcholine M4 receptor positive allosteric modulator (PAM), SUVN-L1305022.

Neuropathic pain affects about 60% of patients with diabetes. The hepatocyte growth factor (HGF)/MET pathway is known to play a critical role in neurogenesis and nervous system repair; thus, its stimulation may provide neuroprotective effects, as well as reduce pain symptoms.

Bit Bio Ltd. has announced the addition to its portfolio of ioGlutamatergic Neurons MAPT N279K and ioGlutamatergic Neurons MAPT P301S disease models for frontotemporal dementia (FTD), and early access to its ioGABAergic Neurons for neurological diseases, including epilepsy, schizophrenia, autism and Alzheimer's disease.

Researchers presented data from a study that aimed to assess the repair potential of acute intermittent hypoxia (AIH) treatment for compression injuries.

Investigators at the École Polytechnique Fédérale de Lausanne (EPFL; Swiss Federal Institute of Technology Lausanne) have identified a broad role for the fragile X mental retardation protein (FMRP) in suppressing antitumor immunity, they reported in the Nov. 18, 2022, issue of Science. The results could lead to new ways to boost antitumor immunity. Scientifically, they also provide new insights into the link between tumors and the nervous system.

Mutations in FMR1, the gene that codes for FMRP, cause fragile X syndrome, a neurodevelopmental syndrome that is characterized by mental retardation and autism-like symptoms.Previous work in the laboratory of Douglas Hanahan, who is the senior author of the Science paper, as well as by other teams had shown that FMRP levels were increased in several tumor types, and increased the chances that those tumors would metastasize.

Previous studies found that the neuronal loss of UBA6 led to decreased dendritic spine density and behavior dysfunction in murine models.

Researchers from Cerevel Therapeutics LLC presented data from a study that aimed to evaluate preclinical antipsychotic properties of M4 agonism while minimizing off-target side effects using novel muscarinic acetylcholine M4 receptor full and partial agonists, CV-0000042 (CVL-042) and CV-0000071, respectively.

Attralus Inc. and Ossianix Inc. have entered into...

Neuropathic pain (NP) is caused by damage or...